Cours suspendu

Communiqués Sage Therapeutics, Inc.

Actions

SAGE

US78667J1088

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 30/07/2025			Varia. 5j.	Varia. 1 janv.
8,680 ^USD	-0,23%		-.--%	-

31/07/25	Supernus Pharmaceuticals finalise l'acquisition de Sage Therapeutics	MT
31/07/25	Sage Therapeutics, Inc. annonce des changements au sein de sa direction	CI

Communiqués

31/07/25	Supernus Pharmaceuticals Completes Acquisition of Sage Therapeutics	AQ
30/07/25	Sage Therapeutics Announces Second Quarter 2025 Financial Results	BU
14/07/25	SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE	BU
19/06/25	SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE	BU
29/04/25	Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates	BU
22/04/25	Kuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law Firm	PR
15/04/25	Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025	BU
12/04/25	SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE	BU
17/03/25	SAGE THERAPEUTICS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sage Therapeutics, Inc. - SAGE	BU
04/03/25	Sage Therapeutics Announces R&D Leadership Transition	BU
11/02/25	Sage Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Highlights Pipeline and Business Updates	BU
28/01/25	Sage Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 11, 2025	BU
27/01/25	Sage Therapeutics Board of Directors Initiates Review of Strategic Alternatives and Rejects Biogen’s Unsolicited Acquisition Proposal	BU
13/01/25	Sage Therapeutics to Present 2025 Strategic Focus at 43rd Annual J.P. Morgan Healthcare Conference	BU
11/01/25	Sage Therapeutics Confirms Receipt of Unsolicited Nonbinding Acquisition Proposal from Biogen	BU
08/01/25	Sage Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025	BU
26/11/24	Sage Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference	BU
21/11/24	Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor in the Treatment of Cognitive Impairment Associated with Huntington's disease	AQ
20/11/24	Sage Therapeutics : Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE 718) in the Treatment of Cognitive Impairment Associated with Huntington's Disease Form 8 K	PU
20/11/24	Sage Therapeutics Announces Topline Results from the Phase 2 DIMENSION Study of Dalzanemdor (SAGE-718) in the Treatment of Cognitive Impairment Associated with Huntington’s Disease	BU
29/10/24	Sage Therapeutics : Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates Form 8 K	PU
29/10/24	Sage Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Pipeline and Business Updates	BU
28/10/24	Shareholders that lost money on Sage Therapeutics, Inc.(SAGE) should contact The Gross Law Firm about pending Class Action - SAGE	PR
23/10/24	Sage Therapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - SAGE	PR
17/10/24	Sage Therapeutics : Management Change/Compensation Form 8 K	PU